The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer

Name: Gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
Uploaded: 2020-07-06T00:00:00Z
Duration: 1 min 58 s
Description: Rachel Riechelmann, MD, PhD, of the AC Camargo Cancer Canter, São Paulo, Brazil, highlights the use of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer as evaluated in a systemic review and meta-analysis. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Rachel Riechelmann • 6 Jul 2020

ESMO WCGIC 2020

Gastrointestinal Cancer Pancreatic Cancer Folfirinox Gemcitabine

Rachel Riechelmann, MD, PhD, of the AC Camargo Cancer Canter, São Paulo, Brazil, highlights the use of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer as evaluated in a systemic review and meta-analysis. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).